Kevin Mansmann, M.D.

Kevin Mansmann 2022
Kevin Mansmann 2022


Recognizing the Signs of Tendonitis and How to Treat it

According to the Bureau of Labor Statistics, tendonitis causes more than 70,000 people to miss work per year. This is just one of many reasons why it is important to understand the symptoms of tendonitis so that you can avoid not only the pain but the inconvenience it...

What are Non-Surgical Treatment Options for a Herniated Disc

The spine consists of 26 bones called vertebrae and between them are cushion-like pads called “intervertebral discs”. The discs serve as shock absorbers for the vertebrae and help provide stability to the spine. When one of these intervertebral discs loses its normal...



  • Arthroplasty- Total Joint Replacement (Hip & Knee)
  • Arthroscopy (Shoulder, Hip & Knee)
  • Sports Medicine
  • Fracture Care – Swiss Technique


  • Residency — Harvard Medical School Combined Orthopaedic Residency Program
  • Fellowship in Adult Reconstructive and Arthritis Surgery (Total Joint Replacement) — Brigham & Women’s Hospital at Harvard Medical School
  • General Surgery — Harborview Medical Trauma Center
  • M.D. — Jefferson Medical College, Thomas Jefferson University


  • American Board of Orthopaedic Surgery


  • American Academy of Orthopaedic Surgeons
  • American Association of Hip & Knee Surgeons
  • International College of Surgeons
  • Founder and Director of the Arthroscopy Research Institute and the Arthroscopic Joint Resurfacing Foundation


Dr. Mansmann has been a U.S. Olympic Ski Team doctor for 15 years, which has allowed him to ski most of the glaciers in Europe. He also served as an orthopaedic consultant to the Philadelphia 76ers since 2008. Dr. Mansmann has been issued 14 patents for the development of advanced innovative technologies for arthroscopic joint resurfacing.

Additionally, Dr. Mansmann has pioneered the CyborGel® Synthetic Cartilage Implant System, designated in November 2020 by the Food and Drug Administration (FDA) as a “Breakthrough Device.” CyborGel® is a novel synthetic hydrogel cartilage implant designed for the treatment of progressive and post-traumatic osteoarthritis. The device mimics and reproduces the structure, microanatomy, and performance of natural joint cartilage. 
The goals of this procedure, which is currently undergoing safety testing for future FDA approval, are to resurface the damaged articular cartilage surface with the implants to aid in functional joint restoration, reduce progressive deterioration of synovial joints, and reduce pain from bone-on-bone wear, thereby forestalling and potentially reducing the need for joint replacement.

Dr. Mansmann brings with him the most innovative and advanced technologies, in both surgical and non-surgical care, in addition to the classical techniques.
DISCLOSURE: Dr. Mansmann is Founder and CEO of Formae Inc., the company that created CyborGel